Physician profile
Vu Q Phan
NPI 1831247667
$41,560.92
in general payments reported to CMS, 2019-2025
99 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,470 · 2020: $1,911 · 2021: $5,529 · 2022: $4,602 · 2023: $5,904 · 2024: $8,596 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Consulting Fee: $6,950 · Education: $1,105 · Long Term Medical Supply Or Device Loan: $299 · Travel and Lodging: $71.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,623.05 |
| Consulting Fee | $6,950.00 |
| Education | $1,105.10 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Travel and Lodging | $71.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,894.46 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Eisai INC. | $3,007.31 | 2019-2025 | |
| Stemline Therapeutics INC. | $2,725.54 | 2022-2025 | Orserdu |
| Cardinal Health 110 LLC | $2,128.24 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $2,023.80 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Pfizer INC. | $1,840.52 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,588.96 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $1,548.30 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $1,425.66 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $1,423.33 | 2019-2025 | Kyprolis, Blincyto, Nplate |
| E.R. Squibb & Sons, L.L.C. | $1,173.57 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $955.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $901.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $862.29 | 2019-2025 | |
| Genzyme Corporation | $714.52 | 2019-2025 |
Show all 95 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $661.15 | 2019-2025 | Polivy, Tecentriq Hybreza, Phesgo |
| Regeneron Healthcare Solutions, INC. | $638.50 | 2019-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $629.12 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $567.28 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $547.04 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $545.63 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Boston Scientific Corporation | $535.13 | 2023-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Astellas Pharma US INC | $527.11 | 2019-2024 | Xtandi, Xospata |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.03 | 2019-2025 | Gilotrif |
| Gilead Sciences, INC. | $390.11 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $382.87 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Seagen INC. | $376.00 | 2019-2025 | Tukysa, Adcetris |
| Aveo Pharmaceuticals, INC. | $373.60 | 2021-2025 | Fotivda |
| Dendreon Pharmaceuticals LLC | $344.25 | 2019-2024 | Provenge |
| Organon LLC | $327.09 | 2022-2025 | Ontruzant |
| Pharmaessentia USA Corporation | $318.23 | 2023-2025 | Besremi |
| Puma Biotechnology, INC. | $314.71 | 2019-2025 | |
| Exelixis INC. | $284.18 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $245.43 | 2023-2025 | Brukinsa |
| Kite Pharma, INC. | $235.53 | 2020-2023 | Yescarta |
| Blueprint Medicines Corporation | $235.42 | 2021-2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $216.98 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $215.28 | 2022-2025 | Bavencio |
| Janssen Pharmaceuticals, INC | $214.35 | 2019-2021 | |
| Taiho Oncology, INC. | $208.91 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $208.49 | 2022-2025 | Vyxeos |
| Glaxosmithkline, LLC. | $204.26 | 2021-2024 | Ojjaara, Jemperli, Zejula |
| Genmab U.S., INC. | $204.02 | 2023-2025 | Epkinly |
| Beone Medicines USA, INC. | $199.20 | 2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $190.28 | 2021-2024 | Xpovio |
| Cardinal Health 108 LLC | $189.84 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $189.02 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Heron Therapeutics, INC. | $182.46 | 2021-2022 | |
| Sobi, INC | $174.59 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $164.34 | 2019-2025 | Onivyde, Somatuline Depot |
| Spectrum Pharmaceuticals INC. | $139.94 | 2023-2025 | Rolvedon |
| Deciphera Pharmaceuticals INC. | $131.04 | 2021-2025 | Qinlock, Romvimza |
| Adaptive Biotechnologies Corporation | $120.63 | 2024 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $111.09 | 2023-2025 | Odomzo, Yonsa |
| Adc Therapeutics America, INC. | $110.33 | 2023-2025 | |
| Tempus Ai, INC | $109.71 | 2024 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $102.46 | 2023-2025 | Monoferric, Cosela |
| Coherus Oncology, INC. | $100.96 | 2022-2025 | Loqtorzi |
| Verity Pharmaceuticals INC. | $91.14 | 2022-2023 | Trelstar |
| Sanofi-Aventis U.S. LLC | $89.95 | 2023 | |
| Agios Pharmaceuticals, INC. | $85.64 | 2020-2025 | Pyrukynd |
| Immunocore Limited | $84.50 | 2024-2025 | Kimmtrak |
| Global Blood Therapeutics, INC. | $75.83 | 2021-2022 | |
| Springworks Therapeutics, INC. | $74.19 | 2024 | Ogsiveo |
| Myovant Sciences INC. | $67.76 | 2021-2022 | |
| Eusa Pharma (US) LLC | $62.48 | 2020-2022 | |
| Mirati Therapeutics, INC. | $61.82 | 2023 | Krazati |
| Janssen Scientific Affairs, LLC | $58.32 | 2023 | Erleada, Akeega |
| Immunogen, INC. | $57.20 | 2023-2024 | Elahere, Elahere |
| Amneal Pharmaceuticals LLC | $49.42 | 2024-2025 | Neupogen, Avastin, Neulasta |
| Mylan Institutional INC. | $47.81 | 2022-2023 | Fulphila, Ogivri |
| Accord Healthcare, INC. | $47.44 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $46.53 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $45.92 | 2023-2025 | Pylarify |
| Servier Pharmaceuticals LLC | $44.60 | 2022 | |
| Kyowa Kirin, INC. | $44.04 | 2020-2023 | Poteligeo |
| Tesaro, INC. | $43.48 | 2019 | |
| Cti Biopharma Corp. | $42.21 | 2023 | Vonjo |
| Dova Pharmaceuticals | $38.86 | 2019-2021 | |
| Novocure INC. | $34.98 | 2025 | Optune Lua (Novottf-200t) |
| Helsinn Therapeutics (U.S.), INC. | $31.99 | 2021-2025 | Akynzeo |
| Chiesi USA, INC. | $29.72 | 2023-2025 | Ferriprox |
| Tersera Therapeutics LLC | $29.58 | 2023 | Quzyttir |
| Sirtex Medical INC | $28.68 | 2024 | Sir-Spheres Microspheres |
| Syndax Pharmaceuticals, INC. | $25.82 | 2025 | |
| Myriad Genetic Laboratories, INC. | $25.40 | 2021 | |
| Iovance Biotherapeutics, INC. | $24.94 | 2025 | Amtagvi |
| Morphosys, US INC. | $24.64 | 2023 | Monjuvi |
| Recordati_rare_diseases_inc. | $24.41 | 2023 | Sylvant |
| Epizyme, INC. | $23.58 | 2021 | |
| Sumitomo Pharma America, INC. | $23.20 | 2024 | Orgovyx |
| Acceleron Pharma, INC. | $19.44 | 2020 | |
| Verastem, INC. | $18.01 | 2019 | |
| G1 Therapeutics, INC. | $16.07 | 2023 | Cosela |
| Azurity Pharmaceuticals, INC. | $15.22 | 2025 | Danziten |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,302.47 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.